AngioDynamics (NASDAQ:ANGO) Lowered to Hold Rating by Wall Street Zen

AngioDynamics (NASDAQ:ANGO - Get Free Report) was downgraded by investment analysts at Wall Street Zen from a "buy" rating to a "hold" rating in a report issued on Saturday.

A number of other research analysts have also commented on ANGO. Weiss Ratings restated a "sell (d-)" rating on shares of AngioDynamics in a research note on Saturday, September 27th. Lake Street Capital initiated coverage on AngioDynamics in a research note on Wednesday, July 16th. They issued a "buy" rating and a $24.00 target price for the company. HC Wainwright restated a "buy" rating and issued a $16.00 target price on shares of AngioDynamics in a research note on Wednesday, July 16th. Finally, Canaccord Genuity Group upped their price target on AngioDynamics from $17.00 to $18.00 and gave the company a "buy" rating in a research report on Friday. Three research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $19.33.

AngioDynamics Trading Down 0.9%

Shares of NASDAQ ANGO opened at $11.64 on Friday. The business has a fifty day simple moving average of $9.94 and a 200 day simple moving average of $9.76. The firm has a market capitalization of $478.17 million, a price-to-earnings ratio of -14.92 and a beta of 0.78. AngioDynamics has a one year low of $5.83 and a one year high of $13.50.

AngioDynamics (NASDAQ:ANGO - Get Free Report) last issued its earnings results on Thursday, October 2nd. The medical instruments supplier reported ($0.10) EPS for the quarter, beating analysts' consensus estimates of ($0.12) by $0.02. The business had revenue of $75.71 million during the quarter, compared to analyst estimates of $72.69 million. AngioDynamics had a negative return on equity of 3.16% and a negative net margin of 10.67%.AngioDynamics's revenue was up 12.1% on a year-over-year basis. During the same period in the prior year, the company posted ($0.11) earnings per share. AngioDynamics has set its FY 2026 guidance at -0.330--0.230 EPS. On average, research analysts anticipate that AngioDynamics will post -0.37 earnings per share for the current fiscal year.

Hedge Funds Weigh In On AngioDynamics

Several hedge funds have recently added to or reduced their stakes in ANGO. GSA Capital Partners LLP bought a new stake in shares of AngioDynamics during the 1st quarter valued at $642,000. GAMMA Investing LLC raised its position in shares of AngioDynamics by 1,281.4% during the 1st quarter. GAMMA Investing LLC now owns 13,897 shares of the medical instruments supplier's stock valued at $130,000 after acquiring an additional 12,891 shares during the last quarter. New York State Common Retirement Fund lifted its stake in AngioDynamics by 667.0% in the first quarter. New York State Common Retirement Fund now owns 54,635 shares of the medical instruments supplier's stock valued at $513,000 after buying an additional 47,512 shares during the period. Principal Financial Group Inc. lifted its stake in AngioDynamics by 25.1% in the first quarter. Principal Financial Group Inc. now owns 120,008 shares of the medical instruments supplier's stock valued at $1,127,000 after buying an additional 24,047 shares during the period. Finally, Phocas Financial Corp. acquired a new position in AngioDynamics in the first quarter valued at about $3,177,000. Institutional investors own 89.43% of the company's stock.

AngioDynamics Company Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.